NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Clinical Guideline Centre (UK). Osteoarthritis: Care and Management in Adults. London: National Institute for Health and Care Excellence (UK); 2014 Feb. (NICE Clinical Guidelines, No. 177.)
Update information: December 2020: in the recommendation on adding opioid analgesics NICE added links to other NICE guidelines and resources that support discussion with patients about opioid prescribing and safe withdrawal management. For the current recommendations, see www.nice.org.uk/guidance/CG177/chapter/recommendations.
I.1. Nutraceuticals
I.1.1. All glucosamine preparations (hydrochloride or sulfate) vs. placebo
Figure 8. Pain (pooled measures)- OA knee
Figure 10. WOMAC function- OA knee
Figure 11. WOMAC stiffness- OA knee
D. 2. All glucosamine preparations (hydrochloride or sulfate) vs. NSAIDs
Figure 15. Lequesne Index- OA Knee
Figure 16. Patient global assessment)- OA Knee
I.3.1. Licensed glucosamine vs. placebo
Figure 18. Pain (pooled measures)
Figure 22. Lequesne Index (continuous)
Figure 23. Lequesne Index (dichotomous)- OA knee (3 months or less)
Figure 24. Minimum joint space width (mm)- OA knee
Figure 25. Mean joint space width (mm)- OA knee
I.3.2. Licensed glucosamine preparations vs. NSAIDs
Figure 28. Pain (pooled measures)
I.3.3. Licensed glucosamine preparations vs. Paracetamol
Figure 31. WOMAC Pain- Long term- Knee OA
Figure 32. Lequesne Index- Long term- Knee OA
I.3.4. Unlicensed glucosamine preparations vs. placebo
Figure 35. OA Knee- Pain (pooled measures)
Figure 36. Knee OA- WOMAC pain
Figure 39. VAS pain on movement- OA knee
Figure 40. VAS pain at rest- OA knee
Figure 41. Patient Global Assessment of disease status score (0–100mm)
I.3.5. Unlicensed glucosamine vs. NSAIDs
Figure 49. Knee OA - Pain (pooled measures)
Figure 50. Knee OA -Lequesne Index
I.3.6. Glucosamine vs. placebo- long term follow up (post- hoc analysis)
Figure 53. Number of patients who had knee replacement (up to 8 years follow up)
I.3.7. Chondroitin v Placebo
Figure 54. OA Knee-Pain- VAS -pooled
Figure 55. OA Knee-Pain WOMAC - Time points greater than 3 months
Figure 56. OA Knee-Function on WOMAC scale- Time points greater than 3 months
Figure 57. OA Knee-Stiffness on WOMAC scale- Time points greater than 3 months
Figure 58. OA Knee-OMERACT-OARSI response- Time points greater than 3 months
Figure 59. OA Knee-Change in minimum joint space width loss- Time points greater than 3 months
Figure 60. OA Knee- SF-36 Physical component- Time points less than 3 months
Figure 61. OA Knee- SF-36 Mental component- Time points less than 3 months
Figure 62. OA Knee- SF-12 Physical component- Time points greater than 3 months
Figure 63. OA Knee- SF-12 Mental component- Time points greater than 3 months
Figure 64. OA Knee- Patient’s global assessment- Time points greater than 3 months
Figure 66. OA Hip- Pain VAS- Time points greater than 3 months
Figure 67. OA Hand- Pain VAS- Time points greater than 3 months
Figure 68. OA Hand- FIHOA score- Time points greater than 3 months
I.3.8. Chondroitin v NSAIDs
Figure 70. OA Knee- Pain WOMAC- Time points greater than 3 months
Figure 71. OA Knee- Function WOMAC- Time points greater than 3 months
Figure 72. OA Knee- Stiffness WOMAC- Time points greater than 3 months
Figure 73. OA Knee- OMERACT-OARSI response – Time points greater than 3 months
Figure 74. OA Knee- Patient’s global assessment of disease status- Time points greater than 3 months
I.3.9. Glucosamine hydrochloride + Chondroitin vs. Placebo
Figure 76. OA Knee- VAS Pain- Short term
Figure 77. OA Knee- SF36 Physical component- Short term
Figure 78. OA Knee- SF36 Mental component- Short term
Figure 79. OA Knee- WOMAC Pain- Long term
Figure 80. OA Knee- WOMAC Function- Long term
Figure 81. OA Knee- WOMAC Stiffness- Long term
Figure 82. OA Knee- Patient Global Assessment- Long term
I.4. Acupuncture
I.4.1. Acupuncture versus sham acupuncture
Figure 90. Pain WOMAC- short term- OA knee with imputed IPD data
Figure 91. Pain VAS- short term- OA knee
Figure 92. Pain Knee Society Score- short term- OA Knee
Figure 93. Function WOMAC- short term- OA Knee
Figure 94. Function Knee Society Score- short term- OA Knee
Figure 95. Stiffness WOMAC- short term- OA Knee
Figure 96. EuroQol- short term- OA knee
Figure 97. SF12 Physical component- short term- OA Knee
Figure 98. SF12 Mental component- short term- OA Knee
Figure 99. SF36 Physical component- short term- OA Knee
Figure 100. SF36 Mental component- short term- OA Knee
Figure 101. Pain WOMAC- long term- OA Knee with imputed IPD data
Figure 102. Function WOMAC- long term- OA Knee
Figure 103. Stiffness WOMAC- long term- OA Knee
Figure 104. SF12 Physical component- long term- OA Knee
Figure 105. SF12 Mental component- long term- OA Knee
Figure 106. SF36 Physical component- long term- OA Knee
Figure 107. SF36 Mental component- long term- OA Knee
Figure 108. OMERACT-OARSI response- long term- OA Knee
Figure 109. Pain VAS- short term- OA Hip
Figure 110. Function Lequesne (hip function index)- short term- OA Hip
I.4.2. Acupuncture versus waiting list control or other active treatments
Figure 111. WOMAC Pain- Short term- OA Knee
Figure 112. VAS Pain- Short term- OA Knee
Figure 113. WOMAC Function- Short term- OA knee
Figure 114. WOMAC Stiffness- Short term- OA Knee
Figure 115. Lequesne Index- Short term- OA Knee
Figure 116. EQ5D- Short term- OA Knee
Figure 117. SF12- Physical component- short term- Knee OA
Figure 118. SF12- Mental component- short term- Knee OA
Figure 119. SF36- Physical component- short term- Knee OA (Change + final scores)
Figure 120. SF36-Mental component- short term- knee OA
Figure 121. WOMAC Pain- long term- Knee OA
Figure 122. WOMAC Function- Long term- OA Knee
Figure 123. WOMAC Stiffness- Long term- OA Knee (change + final scores)
Figure 124. EQ5D- Long term- OA Knee
Figure 125. SF12- Physical component- Long term- OA Knee (change score)
Figure 126. SF12- Mental component- Long term- OA Knee (change score)
Figure 127. SF36-Physical component- Long term- OA Knee (change + final scores)
Figure 128. SF36- Mental component- Long term- OA Knee
Figure 129. OMERACT-OARSI responder criteria- Long term- OA Knee
Figure 130. WOMAC Pain- Short term- OA Hip
Figure 131. WOMAC Function- Short term- OA Hip
Figure 132. WOMAC Stiffness- Short term- OA Hip
I.5. Hyaluronan injections
I.5.1. Knee OA: licensed hyaluronan products vs. placebo or other treatments
I.5.1.1. Hyalgan
Figure 138. OARSI responder criteria
Figure 139. Joint space width (mm)
Figure 140. Joint space width (mm) (after 3 courses of treatment and with stratified subgroups)
Figure 141. Patient global assessment (number of patients improved)
Figure 142. Patient global assessment (number of joints fairly good/good/very good)
Figure 143. Number of patients with injection site pain or painful injection
I.5.1.2. Hylan G-F20
Figure 148. Patient global assessment (0–100 VAS, 100 worst severity)
I.5.1.3. Orthovisc
I.5.1.4. BioHy (Euflexxa, Arthrease)
Figure 156. WOMAC stiffness (more than 13 weeks post-injection)
Figure 157. WOMAC function (more than 13 weeks post-injection)
Figure 158. OARSI responders (more than 13 weeks post-injection)
Figure 159. Patient global assessment (more than 13 weeks post-injection)
Figure 160. HRQoL SF36 (more than 13 weeks post-injection)
Figure 161. Number of adverse events for injection site pain (more than 13 weeks post-injection)
I.5.2. Hyaluronan vs. NSAID
I.5.2.2. Hylan GF20
I.5.3. Hyaluronan vs. Triamcinolone
I.5.3.1. Hylan G-F20
I.5.3.2. Durolane
I.5.3.3. Ostenil
I.5.4. Hyaluronan vs. steroid
I.5.4.1. Hyalgan vs. methylprednisolone acetate
Figure 182. Patient global assessment (number of patients very good/good, excellent/good)
I.5.4.2. Orthovisc vs. 6-methylprednisolone
Figure 183. number of patients reporting skin adverse events
Figure 184. number of patients reporting knee pain after injection
I.5.4.3. Orthovisc vs. betamethasone
Figure 186. Patient global assessment (number of patients good or very good)
I.5.5. Hyaluronan vs. physiotherapy
I.5.5.1. Hylan G-F20
I.5.6. Hyaluronan vs. conventional treatment
I.5.7. Hyaluronan vs. appropriate treatment
I.5.8. Knee OA: unlicensed hyaluronan products vs. placebo or other treatment
I.5.9. Hyaluronan vs. steroid
I.5.9.1. Artz
I.5.10. Hyaluronan vs. exercise
I.6. Knee OA: hyaluronan vs. another hyaluronan
I.6.1. Hyalgan vs. Hylan G-F20
Figure 215. number of patients with local reaction (acute inflammation and pain)
I.6.2. BioHy vs. Hylan G-F20
Figure 219. Patient assessment of treatment (number of patients satisfied or very satisfied)
I.6.3. Orthovisc vs. Hylan G-F20
Figure 223. Patient global assessment (VAS 0–100, 100 worst severity)
Figure 224. SF36 physical functioning
Figure 225. number of patients with local adverse events (more than 13 weeks)
I.6.4. Hylan GF 20 vs. Sinovial
I.6.5. Adant vs. Hyalgan
Figure 228. patient global assessment (number of patients excellent/good)
I.6.6. Fermathron vs. Hyalart
Figure 231. Patient global assessment (number of patients excellent/good)
I.6.7. Hylan GF 20 vs. Variofill
I.6.8. Hyruan vs. Hyal
Figure 236. Adverse events at injection site- number of knees
I.6.9. Go-on vs. Hylagan
Figure 237. VAS pain- 26 weeks
Figure 238. WOMAC pain – 26 weeks
Figure 239. WOMAC function- 26 weeks
Figure 240. WOMAC stiffness- 26 weeks
Figure 241. Lequesne Index- 26 weeks
Figure 242. OARSI OMERACT responders- 26 weeks
Figure 243. Patient Global Assessment (VAS) 26 weeks
Figure 244. Patient global assessment
Figure 245. Number of patients reporting adverse events- 26 weeks
Figure 246. Number of people discontinuing treatment due to adverse events
I.7. Knee OA: hyaluronan vs. different dose of same hyaluronan
I.7.1. Hyalgan: 5 injections vs. 3 injections
Figure 253. Patient global (number of patients assessing response as satisfactory)
I.7.2. Hylan GF 20: 1 × 6mL injection vs. 1 × 4mL injection vs. 2 × 4mL injection vs. 3 × 4mL injection
Figure 254. Adverse events relating to device (1 × 6mL vs. comparisons)
Figure 255. Adverse events relating to device (1 × 4mL vs. comparisons)
Figure 256. Adverse events relating to device (2 × 4mL vs. comparisons)
Figure 257. Adverse events relating to device (3 × 4mL vs. comparisons)
I.7.3. Orthovisc: 4 injections vs. 3 injections
Figure 258. Patient global assessment
Figure 259. Number of patients with skin adverse events
I.7.3.1. Hyaluronan (no formulation stated): 6 injections vs. 3 injections
Figure 260. WOMAC pain- up to 13 weeks post-injection
Figure 261. WOMAC stiffness- up to 13 weeks post-injection
Figure 262. WOMAC function- up to 13 weeks post-injection
Figure 263. Patient global assessment- up to 13 weeks post-injection
Figure 264. SF36- physical function- up to 13 weeks post-injection
I.8. Hip OA: licensed Hyaluronan vs. placebo or other treatment
I.8.1. Hyaluronan vs. Saline
I.8.1.1. Hyalgan
I.8.1.2. Durolane
Figure 268. Local adverse events (post injection flare), < 13 weeks
I.8.2. Hyaluronan vs. Steroids
I.8.2.1. Hyalgan (licensed product)
I.8.2.2. Hylan G-F 20 (licensed product)
Figure 271. Pain WOMAC, >13 weeks
Figure 272. Function WOMAC, >13 weeks
Figure 273. Stiffness WOMAC, > 13 weeks
I.8.2.3. Durolane (licensed product)
Figure 276. Local adverse events(post injection flare), < 13 weeks
I.8.3. Hyaluronan vs. Standard care
I.8.3.1. Durolane (licensed product)
Figure 277. Local adverse events (post injection flare), < 13 weeks
I.9. Hip OA: Unlicensed Hyaluronan vs. placebo or other treatment
I.10. Hip OA: Hyaluronan vs. another hyaluronan
I.10.1. Ostenil vs. Hylan G-F 20 (both licensed products)
I.11. Ankle OA: licensed hyaluronans
I.12. Ankle OA: unlicensed hyaluronans
I.12.1. Hyaluronan vs. saline
I.12.1.1. Supartz
I.12.2. Hyaluronan vs. Exercise
I.13. Trapeziometacarpal joint (Base of thumb) OA: licensed hyaluronans
I.13.1. Hyaluronan vs. Steroids
I.13.1.1. Ostenil vs. Triamcinolone
I.14. First metatarsophalangeal joint (Great toe) OA: licensed hyaluronas
I.14.1. Hyaluronan vs. Saline
I.14.2. Hyaluronan vs. Steroids
I.15. Paracetamol
See CG59.
I.16. NSAIDs
See CG59.
I.17. Diagnosis
I.18. Follow-up
I.18.1. Weight Loss
Weight loss maintained by a dietician versus minimal attention control at one year in rheumatology outpatients in Denmark
Figure 305. WOMAC pain at one year
I.18.2. Exercise
Exercise with booster sessions versus control
I.18.3. Delivery of Care
Practice nurse reinforcement versus education leaflet control at 6 months in primary care in the Netherlands
Figure 309. Dutch AIMS2: Physical domain at 6 months
Figure 310. Dutch AIMS2: Symptoms domain at 6 months
Figure 311. Dutch AIMS2: Social domain at 6 months
Figure 312. Dutch AIMS2: Affect domain at 6 months
GP OA training versus usual care control at 9 months in primary care in Germany
Figure 313. German AIMS2: Lower body domain at 9 months
Figure 314. German AIMS2: Upper body domain at 9 months
Figure 315. German AIMS2: Symptoms domain at 9 months
Figure 316. German AIMS2: Affect domain at 9 months
Figure 317. German AIMS2: Social domain at 9 months
Figure 318. Percentage of patients requiring a prescription of paracetamol at 9 months
Figure 319. Referrals to orthopaedics at 9 months
GP OA training plus practice nurse phone-call reinforcement versus usual care control at 9 months in primary care in Germany
Figure 320. German AIMS2: Lower body domain at 9 months
Figure 321. German AIMS2: Upper body domain at 9 months
Figure 322. German AIMS2: Symptoms domain at 9 months
Figure 323. German AIMS2: Affect domain at 9 months
Figure 324. German AIMS2: Social domain at 9 months
Figure 325. Percentage of patients requiring a prescription of paracetamol at 9 months
Figure 326. Referrals to orthopaedics at 9 months
Pharmacy review versus advice leaflet control at 12 months in primary care in the UK
Figure 327. WOMAC pain at 12 months
Figure 328. WOMAC function at 12 months
Figure 330. Number of patients meeting OMERACT-OARSI responder criteria at 12 months
Figure 331. Change from baseline in Hospital Anxiety and Depression Scale (HADS) at 12 months
Standardised consultation versus usual care control at one year in patients referred to rheumatology in France
Figure 332. NRS pain at one year
Figure 333. WOMAC function at one year
Figure 334. Patient global assesment of disease activity at one year
Figure 335. SF-12: Physical function domain at one year
Clinical nurse specialist versus junior doctor hospital clinic at 48 weeks in patients referred to secondary care in the UK
Figure 336. VAS pain at 48 weeks
- Nutraceuticals
- All glucosamine preparations (hydrochloride or sulfate) vs. NSAIDs
- Acupuncture
- Hyaluronan injections
- Knee OA: hyaluronan vs. another hyaluronan
- Knee OA: hyaluronan vs. different dose of same hyaluronan
- Hip OA: licensed Hyaluronan vs. placebo or other treatment
- Hip OA: Unlicensed Hyaluronan vs. placebo or other treatment
- Hip OA: Hyaluronan vs. another hyaluronan
- Ankle OA: licensed hyaluronans
- Ankle OA: unlicensed hyaluronans
- Trapeziometacarpal joint (Base of thumb) OA: licensed hyaluronans
- First metatarsophalangeal joint (Great toe) OA: licensed hyaluronas
- Paracetamol
- NSAIDs
- Diagnosis
- Follow-up
- Forest plots - OsteoarthritisForest plots - Osteoarthritis
- Rattus norvegicus signal transducer and activator of transcription 2 (Stat2), mR...Rattus norvegicus signal transducer and activator of transcription 2 (Stat2), mRNAgi|58865379|ref|NM_001011905.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...